joint destruction

WRG-28 is a potent and selective, allosteric discoidin domain receptor 2 (ddr2) inhibitor(IC50 : 230 nM)

FR-217840, a novel matrix metalloproteinase inhibitor, successfully suppresses joint destruction and suggest that FR217840 may have potential as a novel anti-rheumatic drug.

BMS-587101 is a small molecule antagonist of LFA-1, which can reduce inflammation and joint destruction in the mouse model of arthritis.

1. Norisoboldine ((+)-Laurelliptine) might be a potential therapeutic agent for rheumatoid arthritis, and it functions through protecting joint destruction as well as regulating the abnormal immune responses. 2. Norisoboldine inhibits the macrophage activation and the resultant production of pro-inflammatory cytokines via down-regulating the activation of MAPKs signaling pathways rather than NF-κB.